Thrombolysis will continue to be the mainstay for acute stroke treatment

Thrombolysis will continue to be the mainstay for acute stroke treatment

Thrombolysis will continue to be the mainstay for acute stroke treatment, despite the recent revolution in neurointerventional clot retrieval. However, as there are ongoing limitations of thrombolysis of bleeding risk and reduced efficacy in large clots – what possible therapeutic advancements can complement or act as an adjuvant to thrombolysis? Neurointervention – effective, but limited […]

Read More

January 2nd, 2017

Regulatory timelines in the Asia-Pacific

An at-a-glance round-up of the arrangements for clinical trial applications in 10 countries in the region. Australia Australia is unique in that its Human Research Ethics Committees (HRECs) have responsibility for the oversight and ongoing monitoring of trials, including reviews and approvals. The first step is submission of the clinical trial to the HREC for […]

Read More

December 30th, 2016
Part III China

Part III: China’s Future in Global Clinical Research

Active international collaboration has facilitated the rise of the Asia-Pacific region in global clinical research. In the first two parts of this blog series, we’ve discussed how Japan and South Korea – whose clinical research environments vary significantly from each other – share many common interests in their pursuit for advancing clinical R&D. The open […]

Read More

December 7th, 2016
Part II Insights on CT environment – Sth Korea

Part II: Insights on the Clinical Trial Landscape of South Korea

Japan has taken significant steps in establishing itself as a major player in the global clinical research community, driving the demand for more clinical trials across East Asia as a result. By officially acknowledging and seeking clinical data from the Asia-Pacific region, Japan is facilitating a dialogue with one of the most powerful and capable […]

Read More

December 5th, 2016
Part I Clinical trial environment in China

Part I – The clinical trial landscape of the Asia-Pacific, Japan

On the heels of our recent post on our presence at this week’s DIA Japan 2015, BBK welcomes Philip Gregory, the General Manager of George Clinical – CRO China as our guest contributor. With more than 20 years of experience in pharmaceutical, biotech and medical device marketing, Mr. Gregory has spent over 14 years supporting the […]

Read More

December 3rd, 2016

South Korea: Clinical trial opportunities and advantages

Over the last 10 years, South Korea has increasingly become a global clinical trial (CT) hub and has established itself as one of the leading CT destinations in the Asia region. In 2015, South Korea approved a total of 675 trials from South Korean and multinational drug makers for early phase studies that would lead […]

Read More

November 19th, 2016

George Clinical now offers operational coverage in Japan

George Clinical has expanded its coverage in Asia to include Japan.

Read More

November 5th, 2014

George Clinical expands in the Asian region

In order to meet the growing needs of our customers, George Clinical has expanded its geographical footprint within Asia. In 2012 we saw the opening of a second George Clinical office in India in Bengaluru to complement our head office in Hyderabad. With many of our large outcomes studies recruiting patients in India there is […]

Read More

April 16th, 2013

required
required
required
required
I wish to subscribe to George Clinical communications.
required

Add George Clinical to your network